ClinicalTrials.gg
Not yet recruitingNCT06830668Updated Feb 17, 2025

Same-Day Restart of B/F/TAF in HIV Patients After NNRTI Discontinuation

A Phase 4 interventional study of Regimen:BIC+FTC+TAF in HIV Infection and HIV, sponsored by National Center for AIDS/STD Control and Prevention, China CDC. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by National Center for AIDS/STD Control and Prevention, China CDC · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.

Planned enrollment
18th of 50
250 · median 145
Started
2025
with 1 other
Phase 4
14 of 67
2 open now
Registered
62nd of 67
by date
Lead sponsor
4 of 67
National Center for AIDS/STD Control and Prevention, China CDC

Among the 67 studies in HIV Infections with a site in China, this one is the 18th largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 in phase 4, and was the 62nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in HIV Infections with a site in China, or all of them as a file.
02

Study summary

In China, free first-line ART regimens typically consist of two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor (NNRTI). As of the end of 2022, approximately 1.135 million individuals were receiving ART, achieving a coverage rate of 92.8%, largely due to participation in free treatment programs. However, around 36,000 patients have discontinued treatment, primarily due to side effects associated with Efavirenz (EFV), a common NNRTI. The challenges posed by side effects and resistance profiles of existing NNRTIs highlight the need for effective re-initiation of ART to improve overall treatment coverage. INSTIs, particularly B/F/TAF (Bictegravir/emtricitabine/tenofovir alafenamide), demonstrates effective viral suppression and a higher barrier to resistance than NNRTIs. B/F/TAF has shown efficacy in patients with resistance mutations, making it a strong candidate for same-day ART re-initiation, especially in resource-limited areas where genotypic resistance testing may be unavailable. This study aims to evaluate the feasibility and effectiveness of rapidly restarting B/F/TAF in patients with treatment interruptions from previous NNRTI regimens.

03

Conditions studied

  • HIV Infection
  • HIV

Browse trials for

Keywords

  • HIV
  • HIV Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with 18 years old or above.
  • Discontinuation of previous NNRTI based regimen for more than 90 days.
  • No known \< 30mL/min or severe hepatic impairment.
  • No known or suspected resistance to BIC.
  • No known pregnancy

Exclusion criteria

Exclusion Criteria:

••Patients who are pregnant.

  • Patients who have abnormal liver and kidney function indicators( class C, \< 30).Hepatitis virus co-infection does not serve as an exclusion criterion.
  • Patients who have historic resistance test indicating drug resistant to BIC or baseline resistance test indicating resistance to BIC.
  • Patients who are psychiatric illness or active tuberculosis co-infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    AIDS patients who discontinued NNRTI for more than 90 days

    HIV patients of any gender, older than 18 years of age, who have been off their prior NNRTI regimen for more than 90 days and who have an HIV-1 viral load greater than 50 copies/uL.In this study, eligible patients will restart treatment on the same day and receive B/F/TAF for one year.We will conduct follow-ups on the patients and carry out routine clinical tests.

    Drug: Regimen:BIC+FTC+TAF

Interventions

  • DrugRegimen:BIC+FTC+TAF

    Same-day restart of "BIC+FTC+TAF" among HIV patients who experienced discontinuation from previous NNRTI-based regimens

06

What researchers measure

Primary outcomes

  1. The efficacy of re-initiation of B/F/TAF

    Evaluate the efficacy following the re-initiation of B/F/TAF as determined by the achievement of HIV-RNA undetectable (\< 50 copies/ml).

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. Drug resistance status

    Describe drug resistance status

    Time frame: From enrollment to the end of treatment at 48 weeks

  2. The reasons for discontinuation of prior therapy

    Describe the reasons for discontinuation of prior therapy

    Time frame: From enrollment to the end of treatment at 1 week

  3. The efficacy of B/F/TAF

    Evaluate the efficacy of B/F/TAF (achievement of HIV-1 RNA\< 50 copies/ml and HIV-1 RNA \< 200 copies/ml) among those participants rapidly restarting B/F/TAF

    Time frame: From enrollment to the end of treatment at Week 12, Week24 and Week 48

  4. The persistence on B/F/TAF .

    Evaluate the persistence on B/F/TAF during the study period and describe the reasons for discontinuation of B/F/TAF if it happens.

    Time frame: From enrollment to the end of treatment at 48 weeks

  5. The changes in parameters of quality of life and treatment satisfaction

    Describe changes in parameters of quality of life and treatment satisfaction

    Time frame: From enrollment to the end of treatment at Week24 and Week 48

  6. The safety and tolerability on B/F/TAF

    Evaluate the safety and tolerability on B/F/TAF during the study period.

    Time frame: From enrollment to the end of treatment at 48 weeks

  7. The emergence of drug resistance

    Describe the emergence of drug resistance developed during the study period.

    Time frame: From enrollment to the end of treatment at 48 weeks

07

Study locations

1 site
  • National Center for AlDS/STD Control and Prevention,China CDC,NO.155, Changbai Road,Changping District,Beijing
    Chian, Beijing 102206, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Dec 2026, 22 months later.

Of 78 non-industry phase 4 interventional studies under HIV Infections, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 45. This study's planned 22 months is below that.

Counting every sponsor, half of 91 studies reached it within 35 months; a quarter within 23 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2025
First posted
Feb 17, 2025
StartEst.
Feb 28, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06830668
Lead sponsor
National Center for AIDS/STD Control and Prevention, China CDC
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Feb 28, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 17, 2025

Study contacts

Yan Zhao, PhD
Contact
zhaoyan@chinaaids.cn
010-58900930

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion